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STUDY PROTOCOL Open Access
INtervention for Cognitive Reserve
Enhancement in delaying the onset of
Alzheimer’s Symptomatic Expression
(INCREASE), a randomized controlled trial:
rationale, study design, and protocol
Daniela C. Moga1,2,3* , Brooke F. Beech3, Erin L. Abner2,3, Frederick A. Schmitt3,4, Riham H. El Khouli5,
Ashley I. Martinez1, Lynne Eckmann6, Mark Huffmyer1,6, Rosmy George3 and Gregory A. Jicha3,4
Abstract
Background: The course of Alzheimer’s disease (AD) includes a 10–20-year preclinical period with progressive
accumulation of amyloid β (Aβ) plaques and neurofibrillary tangles in the absence of symptomatic cognitive or
functional decline. The duration of this preclinical stage in part depends on the rate of pathologic progression,
which is offset by compensatory mechanisms, referred to as cognitive reserve (CR). Comorbid medical conditions,
psychosocial stressors, and inappropriate medication use may lower CR, hastening the onset of symptomatic AD.
Here, we describe a randomized controlled trial (RCT) designed to test the efficacy of a medication therapy
management (MTM) intervention to reduce inappropriate medication use, bolster cognitive reserve, and ultimately
delay symptomatic AD.
Methods/design: Our study aims to enroll 90 non-demented community-dwelling adults ≥ 65 years of age.
Participants will undergo positron emission tomography (PET) scans, measuring Aβ levels using standardized uptake
value ratios (SUVr). Participants will be randomly assigned to MTM intervention or control, stratified by Aβ levels,
and followed for 12months via in-person and telephone visits. Outcomes of interest include: (1) medication appropriateness
(measured with the Medication Appropriateness Index (MAI)); (2) scores from Trail Making Test B (TMTB), Montreal Cognitive
Assessment (MoCA), and California Verbal Learning Test (CVLT); (3) perceived health status (measured with the SF-36). We will
also evaluate pre- to post-intervention change in: (1) use of inappropriate medications as measured by MAI; 2) CR Change
Score (CRCS), defined as the difference in scopolamine-challenged vs unchallenged cognitive scores at baseline and follow-
up. Baseline Aβ SUVr will be used to examine the relative impact of preclinical AD (pAD) pathology on CRCS, as well as the
interplay of amyloid burden with inappropriate medication use.
Discussion: This manuscript describes the protocol of INCREASE (“INtervention for Cognitive Reserve Enhancement in
delaying the onset of Alzheimer’s Symptomatic Expression”): a randomized controlled trial that investigates the impact
of deprescribing inappropriate medications and optimizing medication regimens on potentially delaying the onset of
symptomatic AD and AD-related dementias.
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Background
Alzheimer’s disease (AD) is an important public health issue.
Approximately 5.8 million Americans are currently living
with AD [1], and this number is predicted to nearly triple by
2050 [2]. To forestall an impending crisis, the 2015 National
Alzheimer’s Project Act (NAPA) report emphasized the need
to identify effective prevention strategies to delay onset of
symptomatic AD [3]. The biological disease course of AD
has been elucidated, described as a 10–20 year preclinical
period with progressive accumulation of amyloid plaques
and neurofibrillary tangles, in the absence of symptomatic
cognitive or functional decline [4]. The duration of this
period is theoretically dependent on the rate of pathologic
progression offset by compensatory mechanisms, collectively
referred to as cognitive reserve (CR) [5]. Previous research
has validated the importance of building and preserving CR
to prolong this asymptomatic phase [5–7]. While much em-
phasis has been placed on developing and testing disease-
modifying strategies targeting this preclinical phase of AD
(pAD), little emphasis has been placed on currently available
strategies targeting CR during pAD that may delay progres-
sion to the symptomatic stage of disease. Interventions de-
signed to bolster CR (including aerobic exercise [8, 9],
complex gameplay [10–12], diet [7, 13–16], and pharmaco-
logical interventions [17, 18]) have shown promise, but have
not been proven to delay onset of symptomatic AD [5].
Medication therapy is a fundamental component of clinical
care in older adults, but evidence suggests that pharmaco-
therapy in this population is often inappropriate [19]. Pre-
scribing for older patients can be challenging due to factors
such as age-related changes in adverse effect profiles and
drug metabolism/catabolism, as well as the extensive use of
polypharmacy to address multimorbidity [20, 21]. Lau et al.
investigated medication use in older adults followed by
National Institute on Aging-funded Alzheimer’s Disease
Centers between 2005 and 2007, and estimated that 20% of
those without dementia and 15% of those with dementia re-
ported using at least one potentially inappropriate medica-
tion (PIM) as defined by the 2003 Beers criteria [19].
Another study found that frail elderly patients took an aver-
age of 15 medications (range 6 to 28) and experienced an
average of 8.9 drug-related problems per patient (range 3 to
19), including inappropriate medication use and misuse and
drug–drug and drug–disease interactions [22]. While these
studies investigated PIM use on small, closely followed co-
horts of patients, PIM use among older adults is widespread.
A recently published paper used a nationally representative
sample of the US older adults population and determined
that 42.6% of older adult medication users reported at least
one PIM as defined by the 2012 Beers criteria between 2006
and 2010 [23].
In a randomized controlled trial (RCT) using a patient-
centered, clinician–pharmacist medication therapy manage-
ment (MTM) intervention, we observed a 56% reduction in
inappropriate anticholinergic drug use in older adults en-
rolled in the study [24]. These data document the efficacy
of the MTM intervention to change inappropriate medica-
tion use and potentially delay dementia due to AD by main-
taining CR. Based on our central hypothesis, as depicted in
Fig. 1, interventions that deprescribe inappropriate medica-
tions and optimize treatment regimens for older adults with
complex medical conditions may delay the substantial fi-
nancial and societal impact of dementia due to AD by
maintaining CR.
Here, we describe an RCT designed to expand the
scope of the aforementioned pilot MTM intervention,
from targeting only anticholinergic medications to tar-
geting reduction in all inappropriate medications, bolster
CR, and ultimately delay symptomatic AD. Finding the
right balance between concomitantly treating several
chronic conditions and avoiding medication-related
negative effects is an important objective for healthcare
providers, yet one that might be difficult to achieve [21,
25]. While clinicians regularly monitor and alter medica-
tion regimens when risks appear to outweigh benefits,
the impact of inappropriate medication use is often not
recognized by many healthcare providers. Interdisciplin-
ary team approaches that focus on thorough medication
reviews are designed to address this issue directly. The
addition of a clinical pharmacist with extensive experi-
ence in conducting MTM reviews in older patients adds
value for the brain health care provided to elderly at risk
for PIM use. Our experience suggests that optimal medi-
cation management can be achieved through the devel-
opment of a therapeutic triad including the clinician,
pharmacist, and patient as outlined in Fig. 1.
Objectives
The INtervention for Cognitive Reserve Enhancement in
delaying the onset of Alzheimer’s Symptomatic Expres-
sion (INCREASE) study is designed to address two spe-
cific aims. The first aim is to conduct a 12-month RCT
to evaluate the impact of a patient-centered, pharma-
cist–clinician team MTM intervention in deprescribing
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unnecessary and inappropriate medication, and thus lim-
iting their use. The second aim evaluates the association
of amyloid burden with CR dysfunction (measured as
cognitive reserve change score (CRCS)) to evaluate the
efficacy of delaying symptomatic disease progression.
We hypothesize that higher amyloid burden reduces CR,
thus increasing susceptibility to “unmasking” of cognitive
impairment by environmental stressors such as inappro-
priate medication use, which may hasten the onset of
clinically evident cognitive impairment and dementia.
Our objectives are as follows:
1. Assess the effectiveness of the MTM intervention in
reducing inappropriate medication use over the
study period as determined by the medication
appropriateness index (MAI; Aim 1) [26]
2. Investigate the association of β-amyloid positron
emission tomography (Aβ-PET) and MAI with CR,
operationalized as CRCS = scopolamine challenged
cognitive test performance versus unchallenged per-
formance (Aims 1 and 2)
3. Investigate the effects of the MTM and changes in
MAI on CRCS in participants that are Aβ-PET
positive or negative over the one-year study period
(Aims 1 and 2)
Methods/design
Study design synopsis
The INCREASE study is a single-site, randomized, placebo-
controlled clinical trial currently being conducted at the Uni-
versity of Kentucky (UK). We plan to enroll 90 non-
demented older adults. Participants will be randomly
assigned to treatment with the MTM intervention or to con-
tinue with standard of care procedures. After enrollment, all
participants are followed for 12months. The UK Institutional
Review Board (IRB) approved all study procedures and all
participants provide informed consent to participate (see
Additional file 1). In addition, the study is also monitored by
an independent Data Safety and Monitoring Board (DSMB)
consisting of a geriatrician, a geriatric pharmacist, and a trial
statistician, as well as representatives from the National Insti-
tute on Aging. The DSMB meets every 6 months to review
the progress of the study and evaluate participants’ safety. All
serious adverse events are reported to the IRB and the
DSMB within 24 h. Before implementation, protocol
Fig. 1 Patient-centered medication therapy management intervention to address the complexity of inappropriate medication use and bolster
cognitive reserve
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modifications are approved by the UK IRB, and then re-
ported to the DSMB and ClinicalTrials.gov.
Study participants
Participants will be recruited from Lexington, KY and the
surrounding area, using IRB-approved media outlets, out-
reach activities, physicians engaged in the memory disorders
clinic, and community physician or personal referrals. The
study cohort consists of non-demented, community dwelling
older adults (aged 65 years and over) who regularly take at
least one medication included on the Beers 2015 list. The
complete list of inclusion and exclusion criteria is detailed in
Table 1.
Data collection and study procedures
Data collected from study participants are captured on paper
source documents and entered and managed using electronic
data capture tools hosted at UK [27, 28]. Research Electronic
Data Capture (REDCap) is a secure, web-based software plat-
form designed to support data capture for research studies,
providing 1) an intuitive interface for validated data capture;
2) audit trails for tracking data manipulation and export pro-
cedures; 3) automated export procedures for seamless data
downloads to common statistical packages; and 4) proce-
dures for data integration and interoperability with external
sources. Study procedures are summarized in Fig. 2 and de-
scribed in detail below.
Scopolamine challenge
Scopolamine patches are a widely used, safe, effective,
Food and Drug Administration (FDA)-approved therapy
for prevention of emesis and motion sickness in adults.
FDA-approved dosing indicates a dose of 1.5 mg patch
every 3 days. In the INCREASE study, patches are used
for a more limited period of time, overnight prior to
challenge cognitive testing (≥ 4 h) to allow 90% steady
state blood levels of approximately 87 pg/mL for free
scopolamine and 354 pg/mL for total scopolamine. The
patches are removed immediately after testing is
complete. Following patch removal, plasma levels decline
in a log-linear fashion with an observed half-life of 9.5 h
and normal cholinergic function is generally regained
within 24 h of patch removal.
Scopolamine challenge has been used to assess cogni-
tive vulnerability (i.e., CR) in published studies and has
been shown to influence cognitive test performance at
comparable subcutaneous (SQ) doses [29]. In addition,
the patch is an easier and more tolerable delivery
method than SQ dosing, which would require prolonged
clinic visits (> 3 h to reach steady state with SQ dosing
that could only be reliably administered in clinic).
The concept of the CRCS is designed to operationalize
cognitive reserve as a quantifiable, objective score that
can be compared over time irrespective of, but in
addition to, longitudinal change in unchallenged cogni-
tive test performance. We acknowledge that this calcula-
tion has not been utilized previously in studies but can
Table 1 INCREASE study eligibility criteria
Inclusion criteria Exclusion criteria
1. Age ≥ 65 years 1. Allergy or known intolerance to scopolamine patches
2. Non-demented 2. Narrow-angle glaucoma
3. No previous reaction or contraindication to scopolamine patch, or
medical condition warranting dose adjustment in scopolamine patch
including but not limited to: open angle glaucoma, gastrointestinal or
urinary outlet obstructions, seizures, or psychosis
3. Difficulty swallowing
4. No contraindications to Aβ PET scan including hypersensitivity to PET
ligand (florbetapir) or radiation exposure in the past year that would
exceed acceptable safe annual exposure in combination with the Aβ
PET
4. Stomach or bowel problems (e.g., blockage, muscle weakness,
ulcerative colitis)
5. Medically stable and able to complete all study activities, in the opinion
of the investigator
5. Myasthenia gravis
6. Reporting at least one potentially inappropriate medication as listed in
the Beers 2015 criteria
6. Blockage of the urinary tract
7. Living in the community 7. Seizures
8. Able to identify a study partner who will drive the participant to and
from the scopolamine-challenged visits
8. Psychosis
9. Willing to participate in this intervention study 9. Contraindications to Aβ PET scan including hypersensitivity to PET
ligand (florbetapir) or radiation exposure in the past year that would
exceed acceptable safe annual exposure in combination with the
amyloid β PET
PET positron emission tomography, Aβ amyloid beta
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be deduced from published data on scopolamine chal-
lenge in other paradigms as challenged vs unchallenged
cognitive test scores. A difference equal to 0 would indi-
cate healthy cognitive reserve reflective of the partici-
pant’s ability to tolerate the patch without diminution in
cognitive test scores, whereas change scores lower than
0 (and in excess of measurement error) would indicate
anticholinergic sensitivity as a surrogate quantitative
measure of cognitive reserve [29].
Randomization and blinding
Randomization is stratified by quantitative Aβ standard-
ized uptake values ratios (SUVr), normalized to cerebel-
lum, as determined following the PET scan: SUVr < 1.2,
1.2 ≤ SUVr < 1.4, and SUVr ≥ 1.4 [30, 31]. Utilization of
these three strata (each stratum includes approximately
one-third of the study population) ensures that amyloid
burden will be equally distributed across the treatment
groups. Within SUVr strata, participants are randomized
to the MTM intervention or standard of care with equal
probability. Randomization occurs on the third study
visit (Table 2). Consecutive treatment assignments are
sealed in opaque envelopes by the study statistician and
opened by the study coordinator following the screening
visit, PET scan, and baseline cognitive assessments.
PET scan
Aβ-PET imaging is currently FDA-approved for the detection
of cerebral amyloid deposition in patients with dementia. It
does not currently have an indication for the detection of
cerebral amyloidosis in patients that do not have dementia.
With these caveats in mind, Aβ-PET imaging has been
reliably used to detect pAD across numerous studies, detect-
ing cerebral amyloidosis in approximately one-third of the
cognitively normal population over the age of 65 years [4, 32].
Current clinical use of Aβ-PET scans relies on a subjective
determination of dichotomous presence vs absence of radiola-
bel binding to cortical regions, which is subject to multiple
sources of error, including visual color discrimination and the
experience of the interpreting radiologist. Quantitative SUVR
determinations are more precise and allow for the specifica-
tion of amyloid burden as a continuous variable that will be
leveraged in the current study allowing associations with cog-
nitive test performance and CRCS to be examined secondarily
across the continuum of cerebral amyloid burden that charac-
terizes pAD [33].
For each scan, the participant receives a single intravenous
administration of approximately 370MBq (10mCi) of florbe-
tapir F 18 (fast intravenous push). The injection of the im-
aging agent is followed by a saline flush. After an uptake
period of 50min, participants will be positioned in a head
Fig. 2 INCREASE study procedures. TMTB Trail Making Test B, MoCA Montreal Cognitive Assessment, CVLT California Verbal Learning Test, PET positron
emission tomography, Aβ amyloid beta, SUVr standardized uptake value ratios
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stabilization unit designed for PET/CT scanners. All PET/
CT scans are performed on a Siemens Biograph TruePoint
6-slice (Siemens Healthcare, Erlangen, Germany). Low reso-
lution CT images of the head will be acquired (120 kVp,
FOV 50 cm, pitch 0.55, 0.5 s rotation time, slice thickness 4
mm, care dose). PET images of the brain are then collected
for a 20-min, 3D emission scan. The emission images will be
reconstructed using 256×256 matrix and all pass filter.
Injected dose, time of injection, residual radiotracer within
the syringe after injection, and patient weight and height are
recorded to be used for the standardized uptake value calcu-
lation based on the following equation:
SUV ¼ uptake kBq=mLð Þ
injected dose kBqð Þ=patient weight gð Þ
Image analysis will be done using dedicated PET/CT image
analysis software, Mirada (version XD3, Mirada Medical Ltd,
New Road, Oxford, UK). Multi-planar reconstruction (MPR)
of the axial images of both PET and CT datasets as well
PET/CT fused images are reconstructed in the sagittal and
coronal planes. Change in brain amyloid burden (as assessed
by florbetapir binding and measured by mean cortical stan-
dardized uptake value ratio (SUVr)) will be analyzed. Total
brain SUVr is calculated as described previously by the
AV45-A11 Study Group [33]. Specifically, multiple volumes
of interests (VOI) will be placed on different parts of the cor-
tex (frontal, parietal, temporal, occipital, precuneus, posterior
cingulate regions) as well as the pons and cerebellum. SUV
ratios for each VOI will be generated using the cerebellum
and pons (SUVr denominators).
Study intervention
As the MTM intervention is educational and delivered in
person, complete blinding of treatment assignment is not
possible. However, we are taking the following steps to
minimize potential bias and achieve the maximum level of
blinding possible by this design: (1) when reviewing the
medication list prior to the intervention, the study coordin-
ator, study pharmacist, and clinician are unaware of the
group allocation; (2) data analysis will be blinded to the
intervention.
At enrollment, each participant is asked to bring all pre-
scription and non-prescription medications and supplements
they currently use. In a face-to-face interview, study
personnel collect information on treatment indication, dur-
ation, dose and mode of administration, and adherence [34].
If participants report any adverse effects, study personnel rec-
ord information on the suspected medication, symptomatol-
ogy, and subsequent treatment modification (whether
initiated by the participant or a healthcare provider) [34].
The study pharmacist then reviews the information
and prepares prioritized written recommendations as
follows: (1) a list of potentially inappropriate medica-
tions taken by the patients that are included in, but
are not limited to, the 2015 Beers criteria [35] (the
Table 2 Overview of study procedures
Procedure Screening Baseline cognitive testing Month
3
Month
6
Month
9
End-of-study cognitive testing
Scopolamine
challenged
Non-
challenged
Scopolamine
challenged
Non-
challenged
Study week −5 ± 2 weeks − 4 ± 1 0 ± 1 13 ± 1 26 ± 1 39 ± 1 52 ± 1 56 ± 1
Demographics X
Health history X X X X X X X X
Medication review X X X X X X X X
NAART X
TMTB X X X X
CVLT X X X X
MoCA X X X X
SF-36 X X
ECG X
Physical exam X X
Neurological exam X X
Gait and balance X X X X X
Aβ-PET imaging X
MTM intervention X X X
Telephone follow-up X X
NAART North American Adult Reading Test, TMTB Trail Making Test B, CVLT California Verbal Learning Test, MoCA Montreal Cognitive Assessment, SF-36 Short-
Form 36, ECG electrocardiogram, Aβ amyloid beta, PET positron emission tomography, MTM medication therapy management
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“problem list”); (2) a proposed action for each medi-
cation in the problem list (discontinuation, treatment
modification (including suggested alternative or dose
change), or treatment continuation when medically
necessary); and (3) proposed action for any other pre-
scription or non-prescription medication or supple-
ment taken by the participant that might be
inappropriate and/or unnecessary. Where appropriate,
the proposed alternatives include medications suggested in
the 2015 Beers 2015 criteria as “Alternative medications for
medications in the use of high-risk medications in the elderly
and potentially harmful drug-disease interactions in the eld-
erly quality measures” [35, 36]. All study participants, regard-
less of their group assignment, are provided with educational
materials focused on appropriate medication use and being
an active participant in their healthcare team: “Avoiding
overmedication and harmful drug reactions” (www.Healthi-
nAging.org), “Ten medications older adults should avoid or
use with caution” (www.HealthinAging.org), and “Be an ac-
tive member of your health care team” (https://www.fda.gov/
drugs/resources-you/be-active-member-your-health-care-
team-article).
Throughout study follow-up, the control group re-
ceives standard medical care from their primary care
providers. The MTM intervention is based on
patient-centered principles by addressing the specific
needs of each individual patient, taking into consider-
ation the individual patient’s preferences and values,
and by empowering the patient to take responsibility
and fully participate in the decision-making process
as an equal team player [37–39]. Following the pre-
liminary medication review described above and the
communication between the pharmacist and the clin-
ician, those randomized to the MTM intervention
meet with the pharmacist–clinician team during case
conferences to discuss the problem list and decide on
final recommendations for discontinuation or change
related to inappropriate medications. The final recom-
mendations and their rationale, along with general
medication information, are discussed by the team
with the participant. For the participants included in
the MTM intervention group, the written recommen-
dations and proposed changes are shared with their
primary care providers, who are consulted on the best
approach to improve outcomes. Although recommen-
dations are made, the study team cannot force
changes. For the duration of the study, the study
coordinator contacts the participant every 3 months
to follow-up on the proposed changes during the
MTM intervention and to determine the need for
additional pharmacist evaluations of newly prescribed
medications.
The detailed schedule of study procedures by specific
visits is included in Table 2 and Fig. 3.
Study outcomes
Study outcomes are summarized in Table 3 and de-
scribed in detail below.
Medication Appropriateness Index (MAI)
The MAI provides explicit instructions and examples to
guide rating of medications as “appropriate”, “marginally
appropriate”, or “inappropriate” based on ten criteria [26].
MAI assessments made by a clinical pharmacist and a
physician demonstrated high inter- and intra-rater reliabil-
ity (kappa = 0.83 and 0.92, respectively) [26]. While our
focus is on medications considered potentially inappropri-
ate by the 2015 Beers criteria, all medications reported by
the participants at baseline and follow-up visits are evalu-
ated by the study pharmacist in collaboration with the
study clinician. Medication appropriateness is assessed by
the study pharmacist in a blinded manner, prior to
randomization for the baseline assessment, and without
knowledge of the group assignment at the end of the study
visit. We will also measure the reduction in the number of
PIMs from baseline to the end of the study.
Cognitive reserve
We operationalize a residual measure of CR utilizing se-
quential cognitive testing under a scopolamine chal-
lenge, followed after 4 weeks by unchallenged cognitive
testing, as described in the Scopolamine challenge sec-
tion. The difference in challenged and unchallenged per-
formance is calculated as the cognitive reserve change
score (CRCS) at baseline and the end of study (EOS).
This novel method of operationalizing a cognitive re-
serve measure with an anticholinergic challenge has the
added benefit of minimizing learning effects that may
arise as a result of the sequential cognitive testing.
Several cognitive measures, including Trail Making
Test B (TMTB) [40, 41], Montreal Cognitive Assessment
(MoCA) [42, 43], and California Verbal Learning Test
(CVLT) [44], will be used when calculating CR, each
highlighting different components of cognition. All the
tests are also available in multiple validated test versions,
which can limit learning effects from repeated testing
[45, 46]. TMTB was selected as the primary outcome
measure based on our previously published work on in-
appropriate medication use in older adults [35, 47]. Our
statistical considerations and power analysis are based
on the data from this work. TMTB measures higher
order executive function, which is a prime target for
cognitive changes resulting from PIM use [35, 47], and
has been shown to be a sensitive measure of cognitive
decline in pAD [48]. MoCA and CVLT were chosen as
global cognition and memory measures (respectively)
to allow comparison to other cohorts, including the
longitudinal cohort at the Alzheimer’s Disease Center
at University of Kentucky (UK-ADC) [42, 43].
Moga et al. Trials          (2019) 20:806 Page 7 of 11
Perceived health status
Change in perceived health status is measured to esti-
mate the overall impact of the MTM intervention using
the Short Form Health Survey (SF-36) at baseline and
EOS. The SF-36 is a validated generic instrument that
evaluates eight health concepts categorized into three
major health attributes: (1) functional status (i.e., phys-
ical functioning, social functioning, role limitations due
to physical problems, role limitations due to emotional
problems); (2) well-being (mental health, vitality, bodily
pain); and (3) general health perception (an overall
evaluation of health) [49]. Previous research has reported
that the SF-36 correlates with Sickness Impact Profile
scores, a more thorough health status evaluation that
could not be conducted feasibly in this trial [50, 51].
Sample size
As noted previously, the study will enroll 90 participants.
We estimate that approximately 30 participants will have
elevated Aβ levels (SUVr ≥ 1.4), with the remaining two-
thirds split between the lower SUVr strata described above.
Based on our current and previous studies using MAI
as the primary outcome, we calculated the sample size
to detect a clinically relevant mean difference of 1.0 be-
tween baseline and follow-up assessments for the
Table 3 Study outcomes
Study outcomes
Primary Medication
appropriateness
MAI Change from pre- to post-
intervention
Executive
function
TMTB CRCS: difference in scopolamine-
challenged and unchallenged z-
scores
Secondary Global
cognition
MoCA
Memory CVLT
Perceived
health status
SF-36 Change from pre- to post-
intervention
MAI medication appropriateness index, TMTB Trail Making Test B,
CVLT California Verbal Learning Test, MoCA Montreal Cognitive Assessment,
SF-36 Short-Form 36
Fig. 3 INCREASE study schedule of enrolment, interventions, and assessments (SPIRIT figure). NAART North American Adult Reading Test, TMTB Trail
Making Test B, CVLT California Verbal Learning Test, MoCA Montreal Cognitive Assessment, SF-36 short-form 36, ECG electrocardiogram, Aβ amyloid
beta, PET positron emission tomography, MTM medication therapy management
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intervention group vs no change in the control group.
We will need 17 participants in each group to detect this
difference with 80% power at a significance level (α) of
0.05. As we expect the effect of the intervention to be
even greater for those with pAD, we have based the
power analysis at a mean difference of 1.5 in MAI. Based
on this assumption, for the subgroup analysis of subjects
with pAD, we would need nine participants per group to
detect this difference with 80% power at α = 0.05, and 11
per group to detect this difference with 90% power.
These MAI effect sizes are rather conservative as previ-
ous studies show that medication reconciliation inter-
ventions can determine a mean MAI change ranging
between 1.9 and 17 [52].
Our previous studies have demonstrated that cognitively
intact older adults who used anticholinergic medications
did not show learning effects for TMTB (i.e., scores
remained unchanged over time), while nonusers showed a
statistically significant improvement after 6 years [53].
Our findings are consistent with another study in younger
adults that identified reduced psychomotor and executive
function in participants treated with 0.2mg scopolamine
subcutaneously (− 0.75 and − 0.50 standard deviations, re-
spectively) [54]. Since TMTB involves both psychomotor
and executive function, it is reasonable to assume that we
will observe deficits on this instrument in non-demented
older adult participants challenged with scopolamine.
Thus, we will compute age- and education-adjusted
TMTB z-scores based on normative data for cognitively
intact older adults [41]. Assuming our scopolamine chal-
lenge will induce deficits in cognitively intact older adults
at least at the levels reported in younger adults, we will
need 32 participants per group to detect a 0.50 SD im-
provement in the CRCS z-score with 80% power at α =
0.05, and 14 per group to detect a 0.75 SD improvement
with 80% power in participants with pAD.
Analysis strategy
To examine the effect of the intervention on medication
appropriateness, we will perform analysis of covariance
(ANCOVA), with the dependent variables being the dif-
ference between outcome measures at baseline and EOS,
and the baseline measurement included as a covariate.
Because the SF-36 does not produce a single overall
measure and to reduce the number of comparisons,
multivariate analysis of covariance (MANCOVA) will be
used to simultaneously estimate the effect of the MTM
intervention on the eight SF-36 health concepts. There
are no planned interim analyses for INCREASE. Adverse
events related to study participation are monitored by
the UK IRB and the study DSMB and reported accord-
ing to Federal regulation. At the minimum, the DSMB
meeting is every 6 months.
Discussion
The current paper describes the rationale and protocol
of the INCREASE study, a single-center RCT designed
to investigate (1) the impact of a patient-centered,
pharmacist-clinician team MTM intervention in redu-
cing unnecessary and inappropriate medication use, and
(2) the interplay of deprescribing inappropriate medica-
tion and amyloid burden on cognitive reserve deficits
and decline. Combining state-of-the-art detection of
pAD through Aβ-PET with a unique patient-centered
interdisciplinary MTM intervention is highly innovative,
and directly translatable to clinical practice.
We hypothesize that the burden of pAD pathology will
dampen CR, increasing susceptibility to “unmasking” of
dementia symptoms by environmental stressors such as
inappropriate medication use. In addition, by reducing
CR, inappropriate medication use may hasten the onset
of clinically evident dementia, prolonging the symptom-
atic phase of disease where health care costs are max-
imally incurred. Our preliminary work demonstrates
that such impact is both feasible and achievable through
practical establishment of procedures and policies de-
signed to evaluate and reduce inappropriate medication
use in older adults. The INCREASE study directly ad-
dresses a fundamental gap in existing knowledge on how
MTM interventions may prove beneficial in delaying AD
onset, shortening the overall duration of symptomatic
disease expression, and reducing healthcare costs.
Some potential limitations of the current study lie in
the use of the CRCS measure, which has not been previ-
ously validated. This concept, however, is based on sci-
entific data that demonstrate that such a measure exists
[29], that it can be calculated easily, and that such an ap-
proach can move to the field of intervention in pAD for-
ward [32]. Furthermore, its calculation is in line with
other methods being developed to operationalize CR
[55]. Regardless, the INCREASE study is strengthened
by preliminary interventional data demonstrating that
our primary outcome measure of MAI change is achiev-
able within the proposed study design. The potential
economic health impact of the study warrants explor-
ation of this approach to the preclinical phase of AD
and reducing the duration of symptomatic disease,
where most health expenditures lie.
At the time of writing, recruitment and enrollment
are ongoing and are expected to be completed by
early 2020. Follow-up measures will be completed by
early 2021 with results expected to become available
in late 2021.
Trial status
– Current protocol version number and date: version
6, dated August 27, 2019
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– Date recruitment began: March 23, 2017
– Approximate date when recruitment will be
completed: March 31, 2020
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-019-3993-0.
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